Maurice Zauderer

Vaccinex (United States) — United States

Neuroscience · Life Sciences

27h-index2.1kcitations175works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Axon Guidance and Neuronal Signaling(81), T-cell and B-cell Immunology(23), Immunotherapy and Immune Responses(22), Monoclonal and Polyclonal Antibodies Research(20), Phagocytosis and Immune Regulation(20)

Publications174 total

Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders
Alzheimer s & Dementia·2025Open Access
22 Neoadjuvant pepinemab enhances immune checkpoint blockade in metastatic melanoma characterized by biomarkers of TME reprogramming including tertiary lymphoid structures
Regular and Young Investigator Award Abstracts·2025Open Access
Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.
Journal of Clinical Oncology·2025· 1 cited
Abstract 3975: Regulating dendritic cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity
Cancer Research·2025
Abstract 6007: Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma
Cancer Research·2025
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases
Expert Opinion on Investigational Drugs·2025· 5 cited
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
Alzheimer s & Dementia·2024· 2 citedOpen Access
1100 Discovery of high affinity functional antibodies specific for CXCR5, P2X7 and other multi-pass membrane receptors
Regular and Young Investigator Award Abstracts·2024Open Access
747 Pepinemab a semaphorin 4D blockade antibody in combination with immune checkpoint therapies induces mature lymphoid aggregates correlating with clinical outcomes
Regular and Young Investigator Award Abstracts·2024Open Access
Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer.
Journal of Clinical Oncology·2024
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)
Pediatric Blood & Cancer·2024· 2 citedOpen Access
A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
Journal of Clinical Oncology·2024
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
Regular and Young Investigator Award Abstracts·2023Open Access
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26<sup>hi</sup> T cell in patients with resectable stage III melanoma
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Use of poxvirus display to select antibodies specific for complex membrane antigens
mAbs·2023· 2 citedOpen Access
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.
Journal of Clinical Oncology·2023
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
Journal of Clinical Oncology·2023· 4 cited
SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study
Alzheimer s & Dementia·2023· 3 citedOpen Access
Data from Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
2023Open Access
Supplementary Figures 1-8 from Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Ernest Smith(19), Elizabeth E. Evans(15), Terrence L. Fisher(11), Christine Reilly(9), John E. Leonard(9), Alan S. Jonason(6), Crystal Mallow(6), Mark Paris(6), Alan Howell(6), Laurie A. Winter(6), Vikas Mishra(5), Ekaterina Klimatcheva(4), Sebold Torno(4), Holm Bußler(4), Maria Scrivens(4), Jennifer Seils(4), Melinda A. Borrello(4), Leslie Balch(4), Tracy Pandina(3), Janaki Veeraraghavan(3)